Suppliers and packagers for generic pharmaceutical drug: CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE

CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Am Regent	MULTRYS	cupric sulfate; manganese sulfate; selenious acid; zinc sulfate	SOLUTION;INTRAVENOUS	209376	NDA	American Regent, Inc.	0517-9302-25	25 VIAL, SINGLE-DOSE in 1 TRAY (0517-9302-25) / 1 mL in 1 VIAL, SINGLE-DOSE (0517-9302-01)	2021-09-01
Am Regent	MULTRYS	cupric sulfate; manganese sulfate; selenious acid; zinc sulfate	SOLUTION;INTRAVENOUS	209376	NDA	American Regent, Inc.	0517-9305-25	25 VIAL, SINGLE-DOSE in 1 TRAY (0517-9305-25) / 1 mL in 1 VIAL, SINGLE-DOSE (0517-9305-01)	2020-09-29
Am Regent	TRALEMENT	cupric sulfate; manganese sulfate; selenious acid; zinc sulfate	SOLUTION;INTRAVENOUS	209376	NDA	American Regent, Inc.	0517-9302-25	25 VIAL, SINGLE-DOSE in 1 TRAY (0517-9302-25) / 1 mL in 1 VIAL, SINGLE-DOSE (0517-9302-01)	2021-09-01
Am Regent	TRALEMENT	cupric sulfate; manganese sulfate; selenious acid; zinc sulfate	SOLUTION;INTRAVENOUS	209376	NDA	American Regent, Inc.	0517-9305-25	25 VIAL, SINGLE-DOSE in 1 TRAY (0517-9305-25) / 1 mL in 1 VIAL, SINGLE-DOSE (0517-9305-01)	2020-09-29

Pharmaceutical Supply Chain Analysis: Copper, Manganese, Selenium, and Zinc Sulfates

Last updated: February 19, 2026

This report analyzes the global supply landscape for four critical inorganic pharmaceutical ingredients: cupric sulfate, manganese sulfate, selenious acid, and zinc sulfate. The analysis identifies key manufacturers, production capacities, regulatory considerations, and potential supply chain risks associated with each compound. The data presented is intended to inform strategic sourcing and investment decisions for pharmaceutical companies.

What are the primary pharmaceutical applications for these sulfate compounds?

Cupric sulfate, manganese sulfate, selenious acid, and zinc sulfate are essential components in various pharmaceutical preparations, primarily due to their roles as trace elements in nutritional supplements, intravenous solutions, and specific therapeutic agents.

• Cupric Sulfate (Copper Sulfate)
  • Nutritional Supplements: Provides essential copper for enzymatic functions, red blood cell formation, and connective tissue health.
  • Intravenous Solutions: Used in parenteral nutrition to prevent or treat copper deficiency.
  • Antidotes: Historically used in specific poisoning treatments, though less common now.
  • Ophthalmic Solutions: Exhibits mild antiseptic properties.
• Manganese Sulfate
  • Nutritional Supplements: Essential for bone formation, metabolism, and antioxidant enzyme activity.
  • Intravenous Solutions: Included in parenteral nutrition to address manganese deficiency.
  • Antioxidants: Supports the function of superoxide dismutase.
• Selenious Acid (Selenium Dioxide)
  • Nutritional Supplements: Source of selenium, vital for thyroid hormone metabolism, antioxidant defense, and immune function.
  • Intravenous Solutions: Administered to prevent or treat selenium deficiency in patients requiring parenteral nutrition.
  • Anticancer Research: Selenium compounds are subjects of ongoing research for their potential role in cancer prevention and treatment.
• Zinc Sulfate
  • Nutritional Supplements: Critical for immune function, wound healing, DNA synthesis, and cell division.
  • Intravenous Solutions: A standard component of parenteral nutrition to prevent or correct zinc deficiency.
  • Ophthalmic Solutions: Used for its astringent and mild antiseptic properties.
  • Gastrointestinal Health: May be used to manage diarrhea in specific contexts.

Who are the leading global manufacturers of these pharmaceutical ingredients?

The manufacturing of high-purity inorganic salts for pharmaceutical use is concentrated among a limited number of specialized chemical producers, often with multi-regional operations. The primary focus is on meeting stringent pharmacopoeial standards (USP, EP, JP).

Cupric Sulfate Manufacturers

Major suppliers for pharmaceutical-grade cupric sulfate include:

• American Elements (USA): Offers a wide range of high-purity inorganic compounds.
• Merck KGaA (Germany): A significant supplier of laboratory and pharmaceutical chemicals.
• Sigma-Aldrich (now part of Merck KGaA) (USA/Germany): Renowned for high-purity reagents and active pharmaceutical ingredients (APIs).
• Fisher Scientific (USA): Distributes a broad portfolio of laboratory chemicals.
• Fujian Quanneng Chemical Co., Ltd. (China): A significant producer of copper sulfate, with capabilities for higher purity grades.
• Weifang Huaxia Chemical Co., Ltd. (China): Another major Chinese producer of copper sulfate.

Manganese Sulfate Manufacturers

Key global producers of pharmaceutical-grade manganese sulfate include:

• American Elements (USA)
• Merck KGaA (Germany)
• Sigma-Aldrich (Merck KGaA) (USA/Germany)
• Fisher Scientific (USA)
• Hubei Xingfa Chemicals Group Co., Ltd. (China): A large-scale producer of phosphorus chemicals and derivatives, including manganese sulfate.
• Shandong Xinhua Pharmaceutical Co., Ltd. (China): While primarily known for APIs, they also produce inorganic salts.

Selenious Acid Manufacturers

The market for high-purity selenious acid is more specialized due to selenium's toxicity and specific handling requirements.

• American Elements (USA): A primary source for high-purity selenium compounds.
• Merck KGaA (Germany): Supplies selenious acid for laboratory and pharmaceutical applications.
• Sigma-Aldrich (Merck KGaA) (USA/Germany)
• Alfa Aesar (Thermo Fisher Scientific) (USA): Offers a range of research chemicals, including selenium compounds.
• Chemsources LLC (USA): Specializes in sourcing rare and high-purity chemicals.
• Bihui Chemical Co., Ltd. (China): Produces selenium compounds, with some grades suitable for pharmaceutical use.

Zinc Sulfate Manufacturers

Numerous manufacturers produce zinc sulfate, with a subset focusing on pharmaceutical grades.

• American Elements (USA)
• Merck KGaA (Germany)
• Sigma-Aldrich (Merck KGaA) (USA/Germany)
• Fisher Scientific (USA)
• Zhonghong Chemical Co., Ltd. (China): A substantial producer of zinc salts.
• Weifang Haizhiyuan Chemical Factory (China): Manufactures various zinc compounds, including pharmaceutical grades.
• United States Zinc Corporation (USA): A significant North American producer.

What is the estimated global production capacity and market size for these compounds?

Estimating exact global production capacities for pharmaceutical-grade inorganic salts is challenging due to proprietary data and the dual use of many industrial-grade products. However, broad market assessments can be made.

• Cupric Sulfate: The global market for copper sulfate is substantial, with an estimated size of over USD 700 million in 2022. Pharmaceutical grades represent a smaller but high-value segment. Production capacity is in the hundreds of thousands of metric tons annually, with significant output from China, the US, and Europe.
• Manganese Sulfate: The market for manganese sulfate is driven by agricultural and industrial applications, with an estimated global market size of around USD 500 million. Pharmaceutical-grade production is a fraction of this, likely in the thousands of metric tons annually. Key producing regions include China, India, and the US.
• Selenious Acid: This is a niche market. Global production is likely in the low hundreds to low thousands of metric tons per year, with a higher value per unit due to specialized processing and purity requirements. The market size is estimated to be in the tens of millions of USD. Production is concentrated among specialty chemical manufacturers in the US, Europe, and increasingly, China.
• Zinc Sulfate: The global zinc sulfate market is significantly larger, estimated at over USD 1.2 billion, driven by agriculture, industrial processes, and animal feed. Pharmaceutical grades constitute a smaller portion, likely in the tens of thousands of metric tons annually. Production is widespread, with major capacities in China, India, Europe, and North America.

Production capacities for pharmaceutical grades are often flexible and can be scaled up by manufacturers producing industrial grades, provided they implement the necessary purification and quality control measures.

What are the key regulatory requirements and pharmacopoeial standards that govern their pharmaceutical use?

Adherence to stringent regulatory frameworks and pharmacopoeial standards is paramount for pharmaceutical-grade inorganic salts. These ensure safety, efficacy, and consistent quality.

• Pharmacopoeial Standards:
  • United States Pharmacopoeia (USP): Sets the official standards for quality, purity, strength, and consistency of medicines, food ingredients, and dietary supplements manufactured, sold, or held for sale in the United States. Specific monographs exist for Cupric Sulfate, Manganese Sulfate, and Zinc Sulfate. Selenious acid is often referenced within broader selenium compound monographs or as an intermediate.
  • European Pharmacopoeia (EP): The equivalent standard for Europe, published by the European Directorate for the Quality of Medicines & HealthCare (EDQM). It also contains specific monographs for these compounds.
  • Japanese Pharmacopoeia (JP): The official compendium for pharmaceuticals in Japan.
  • Other National Pharmacopoeias: India (IP), British Pharmacopoeia (BP), etc.
• Good Manufacturing Practices (GMP): Manufacturers must adhere to GMP regulations to ensure the consistent production and control of drugs according to quality standards. This covers all aspects of production, from raw materials, premises, and equipment to the training and personal hygiene of staff.
• FDA and EMA Regulations: Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) oversee the approval and manufacturing of pharmaceutical ingredients. Suppliers often need to provide documentation such as Drug Master Files (DMFs) for their products to support drug product applications.
• Impurity Limits: Pharmacopoeias specify strict limits for heavy metal impurities (e.g., lead, arsenic, cadmium), as well as other potential contaminants. The allowable levels are significantly lower for pharmaceutical grades compared to industrial grades.
• Assay and Identification: Specific tests are required to confirm the identity and determine the potency (assay) of the active ingredient.
• Loss on Drying/Water Content: Limits are set for moisture content, which can affect stability and potency.
• Trace Elements: While these compounds are intended to provide specific trace elements, the absence or strict control of other undesirable trace metals is crucial.

Manufacturers must maintain robust quality management systems and undergo regular audits by regulatory authorities and their pharmaceutical clients.

What are the primary risks and challenges in the supply chain for these pharmaceutical ingredients?

The supply chain for pharmaceutical-grade inorganic salts is subject to several risks and challenges that can impact availability, cost, and quality.

• Geopolitical Instability and Trade Wars:
  • Many key raw materials and manufacturing hubs are located in specific geographic regions (e.g., China for many inorganic chemicals). Geopolitical tensions, trade disputes, and tariffs can disrupt supply chains and increase costs.
  • Export restrictions or sudden policy changes in major producing countries can lead to shortages.
• Raw Material Availability and Price Volatility:
  • The production of these sulfates relies on precursor chemicals and elemental metals. Fluctuations in the global commodity markets for these upstream materials can directly impact the cost and availability of the final pharmaceutical ingredient.
  • For example, copper and zinc prices are subject to global demand from industries like electronics, construction, and automotive.
• Environmental Regulations and Compliance:
  • The chemical industry, particularly inorganic salt production, is often subject to stringent environmental regulations concerning emissions, wastewater treatment, and waste disposal.
  • Increased regulatory scrutiny can lead to higher production costs, plant closures, or capacity reductions in certain regions if compliance is not met. This is particularly relevant for selenium compounds.
• Quality Control and Counterfeiting:
  • Ensuring the consistent high purity required for pharmaceutical use is a continuous challenge. Differences in manufacturing processes and quality control between suppliers can lead to batch-to-batch variability.
  • The risk of counterfeit or substandard materials entering the supply chain is present, especially in less regulated markets, necessitating rigorous supplier qualification and testing.
• Logistics and Transportation:
  • Global transportation networks can be affected by port congestion, shipping container shortages, fuel price volatility, and unforeseen events (e.g., pandemics, natural disasters), leading to delivery delays and increased freight costs.
  • The handling of certain chemicals, like selenious acid, requires specialized packaging and transport due to toxicity.
• Limited Number of Specialized Manufacturers:
  • For high-purity grades and specialized compounds like selenious acid, the number of qualified manufacturers is relatively small. This concentration increases reliance on a few key suppliers and can amplify the impact of any disruption.
• Lead Times:
  • The production of pharmaceutical-grade materials often involves extended lead times due to the multi-step purification processes and rigorous quality testing required before release.

What strategies can be employed to mitigate supply chain risks?

Pharmaceutical companies can implement several strategic measures to enhance the resilience of their supply chains for these critical inorganic ingredients.

• Supplier Diversification and Dual Sourcing:
  • Identify and qualify multiple suppliers across different geographic regions for each critical ingredient. This reduces dependence on a single source and provides alternatives in case of disruption.
  • Establish dual-sourcing strategies where feasible, even if one supplier is primary, to ensure continuity.
• Robust Supplier Qualification and Auditing:
  • Conduct thorough due diligence on potential suppliers, including on-site audits of their manufacturing facilities and quality management systems.
  • Verify compliance with GMP and relevant pharmacopoeial standards. Regular re-audits are essential.
• Long-Term Contracts and Strategic Partnerships:
  • Negotiate long-term supply agreements with key suppliers to secure pricing and guaranteed volumes.
  • Develop strategic partnerships with critical suppliers, fostering open communication and collaboration on forecasting and risk management.
• Inventory Management and Buffer Stocks:
  • Maintain appropriate levels of safety stock for critical ingredients. The optimal level requires balancing inventory holding costs against the risk of stock-outs.
  • Consider strategic placement of inventory in different geographic locations to buffer against regional disruptions.
• Enhanced Supply Chain Visibility and Monitoring:
  • Utilize supply chain management software and real-time tracking to monitor the status of shipments and identify potential delays early.
  • Proactively monitor geopolitical events, regulatory changes, and market trends that could affect supply.
• Regulatory Intelligence and Compliance Support:
  • Stay informed about evolving regulatory requirements in key markets.
  • Ensure suppliers have robust compliance programs and provide necessary documentation (e.g., DMFs, Certificates of Analysis).
• Geographic Risk Assessment:
  • Map the supply chain to identify concentrations of suppliers or raw material sources in high-risk regions.
  • Explore opportunities to source from regions with more stable political and regulatory environments.
• Technical Collaboration with Suppliers:
  • Work closely with suppliers on process improvements, impurity profiling, and analytical method validation to ensure consistent quality and address any emerging issues.

What is the outlook for innovation and new manufacturing technologies in this sector?

Innovation in the manufacturing of pharmaceutical-grade inorganic salts is primarily focused on process optimization, cost reduction, and enhanced environmental sustainability rather than entirely novel chemical entities.

• Continuous Manufacturing and Process Intensification:
  • Adoption of continuous processing technologies can lead to more efficient, consistent, and cost-effective production compared to traditional batch processes. This can reduce plant footprint and energy consumption.
• Advanced Purification Techniques:
  • Development of more efficient and selective purification methods (e.g., advanced membrane filtration, chromatography) to achieve higher purity levels with fewer steps and reduced waste.
• Green Chemistry Principles:
  • Increasing emphasis on using environmentally friendly solvents, reducing waste generation, and improving energy efficiency throughout the manufacturing process. This aligns with corporate sustainability goals and tightening environmental regulations.
• Digitalization and Automation:
  • Implementation of Industry 4.0 technologies, including advanced process control, real-time data analytics, and automation, to improve process efficiency, reduce human error, and enhance quality consistency.
• Sustainable Sourcing of Raw Materials:
  • Focus on sourcing raw materials from suppliers who adhere to sustainable mining and extraction practices, particularly for metals like copper and zinc.
• Recycling and Circular Economy Approaches:
  • Exploring methods for recycling or recovering trace metals from industrial waste streams to create a more circular supply chain, although this is more challenging for high-purity pharmaceutical grades.

While breakthroughs in the fundamental chemistry of these basic salts are unlikely, continuous improvements in manufacturing technology are expected to enhance efficiency, quality, and sustainability in their production for pharmaceutical applications.

Key Takeaways

• Pharmaceutical-grade cupric sulfate, manganese sulfate, selenious acid, and zinc sulfate are critical components in nutritional support and specific therapies, necessitating high purity and strict quality control.
• The global supply base for these ingredients is concentrated among specialized chemical manufacturers, with significant production capacity in China, the US, and Europe.
• Adherence to USP, EP, JP, and GMP standards is non-negotiable, requiring robust quality management systems from suppliers.
• Supply chain risks include geopolitical instability, raw material price volatility, stringent environmental regulations, and potential quality control failures.
• Mitigation strategies involve supplier diversification, long-term contracts, enhanced supply chain visibility, and rigorous supplier qualification.
• Innovation in manufacturing focuses on continuous processing, advanced purification, green chemistry, and digitalization to improve efficiency, quality, and sustainability.

Frequently Asked Questions

1. What is the typical shelf life for pharmaceutical-grade zinc sulfate? The typical shelf life for pharmaceutical-grade zinc sulfate, when stored under recommended conditions (cool, dry, protected from light), is generally between two to five years. Specific expiry dates are determined by the manufacturer based on stability studies.
2. Are there significant price differences between industrial and pharmaceutical grades of manganese sulfate? Yes, pharmaceutical-grade manganese sulfate is typically significantly more expensive than industrial grades. This premium reflects the extensive purification, rigorous quality testing, GMP compliance, and regulatory documentation required to meet pharmacopoeial standards.
3. How does the sourcing of selenium for selenious acid differ from copper or zinc? Selenium is a scarcer element than copper or zinc, and its extraction and processing are more specialized. Furthermore, due to selenium's toxicity, the handling and purification of selenious acid require more stringent safety protocols and specialized equipment, contributing to higher production costs and a more limited supplier base.
4. What is the primary challenge in ensuring consistent quality for cupric sulfate used in parenteral nutrition? The primary challenge is controlling and minimizing the levels of heavy metal impurities, such as lead, arsenic, and cadmium, to well below pharmacopoeial limits. These impurities can have significant toxicological effects when administered intravenously, making ultra-high purity essential.
5. Can a pharmaceutical company easily switch suppliers for selenious acid if their primary supplier experiences a disruption? Switching suppliers for a critical pharmaceutical ingredient like selenious acid is a complex and time-consuming process. It requires extensive supplier qualification, analytical method validation, stability testing of the finished drug product with the new supplier's material, and often regulatory filings or amendments to existing drug applications, which can take many months.

Citations

[1] Grand View Research. (2023). Copper Sulfate Market Size, Share & Trends Analysis Report.

[2] MarketsandMarkets. (2023). Manganese Sulfate Market.

[3] Mordor Intelligence. (2023). Selenium Market.

[4] Research and Markets. (2023). Zinc Sulfate Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast.

[5] United States Pharmacopeia. (n.d.). USP-NF Online. Retrieved from https://www.uspnf.com/

[6] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Ph. Eur. 11.0. Retrieved from https://www.edqm.eu/